Enhancing the depth and durability of patient responses to CAR T cell therapy

Abstract

<div class="authors authors-lg"><div class="author"><div class="author-img"><img src="https://cdn.insights.bio/uploads/Brogdon photo.png" data-image="1"></div><div class="author-det"> <b>Jennifer Brogdon, PhD</b>, is Executive Director, Head of Cell Therapy Research, in the Department of Exploratory Immuno-Oncology of the Novartis Institutes for BioMedical Research (NIBR) in Cambridge, MA. Jennifer leads development of next generation CAR-T cell therapies for oncology and is responsible for driving innovation, strategy and building a therapeutic pipeline from target discovery to first in human (FIH) clinical studies. Jennifer has broad expertise in antibody, small molecule and cell &amp; gene therapy programs. She helped drive the development of Kymriah – the first CAR-T cell therapy approved by the FDA – and received the Novartis Distinguished Scientist Award for that work and other contributions to novel therapies for multiple hematological and solid malignancies. Her drug discovery experience includes &gt;14 distinct therapeutic immuno-oncology programs that have reached Phase I/II clinical trials. She holds a PhD in Immunology from Duke University and a postdoctoral fellowship in Immunobiology from Yale University. </div></div></div>